Avillion has signed a clinical co-development agreement with Pearl Therapeutics Inc., a wholly owned subsidiary of AstraZeneca, to advance PT027 through a global clinical development program for the treatment of asthma.
PT027 is an investigational fixed dose combination of budesonide (an inhaled corticosteroid) and albuterol (a short-acting beta-2 agonist). Avillion will be responsible for developing PT027 through an extensive clinical development programme and will finance the programme through to regulatory approval.
Allison Jeynes-Ellis, MD, chief executive officer of Avillion, said, "This new collaboration is another great example of how our innovative clinical development model and exceptional operational capabilities can be used to bolster the productivity of our partners' development pipeline. We have already demonstrated the success of our approach in our partnerships with Pfizer and Merck KGaA. We are looking forward to initiating this exciting clinical development program for PT027 in asthma."